Inoviv careers

Our mission is to accelerate the world’s transition to precision medicine, through application of our omics technologies to drug development and healthcare.

60% of drugs don’t work and over 92% of clinical trials fail. This causes millions of deaths each year as well as over $100bn lost for the pharmaceutical industry. Using our new targeted proteomics technology, we can establish the unique molecular signature of each patient’s disease. This increases clinical trial success rates and ultimately helps deliver drugs to patient responders in healthcare settings. We have pharmaceutical clients in the US, Europe and Asia.

We are supported by advisors from Oxford University, Imperial College London, King’s College London, Charité University Hospital and MolecularMD (ICON). We are also backed by the world’s leading talent investor, Entrepreneur First.